tbuckley/cabot-search huggingface dataset:
Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: A phase II feasibility study.
Authors: Erica L. Mayer, Adrienne Brana Gropper, Nadine M. Tung, Michaela Jane Higgins, Tiffany A. Traina, William Thomas Barry, Eric P. Winer, Harold J. Burstein
Journal: Journal of Clinical Oncology (2014)

TPS654 Background: Cell cycle inhibition is a target of interest for novel cancer therapeutics. P is an orally active inhibitor of CDK4/6, causing cell cycle arrest at the G1-S transition. In an interim analysis of a phase II first-line study in HR+ metastatic breast cancer (MBC), patients (pts) randomized to letrozole (L) plus P had prolonged progression-free survival compared with L alone (26.1 vs 7.5 mos, HR 0.37, p<0.001) (Finn et al SABCS 2012). The most common toxicity with P is neutropenia, typically non-cumulative and uncomplicated. Given observed benefits of LP in HR+ MBC, exploring the feasibility of P in the adjuvant setting is warranted. Methods: This is a phase II single arm trial evaluating the feasibility of 2 yrs of combination P and adjuvant ET. Eligible pts are postmenopausal, with HR+ stage II (not T2N0)-III invasive breast cancer. Pts must have demonstrated tolerance of adjuvant aromatase inhibitor (AI) by completion of 3-24 mos of AI without significant adverse events (AE), with plan for at least 2 more yrs of AI. Pts will receive P at 125 mg daily, 3 wk on/1 wk off in a 28d cycle, plus continuous physician’s choice AI (L, anastrozole, or exemestane), for planned duration 2 yrs. Neutropenia monitoring occurs every 2 wks for the first 3 cycles, then monthly for the duration of treatment. Pts may be removed from study for toxicity, non-adherence, or other events related to tolerability; pts who recur or complete 2 yrs of therapy will be censored for the primary endpoint. The primary objective is to evaluate the treatment discontinuation rate at 2 yrs; if the rate is >50%, the treatment duration will not be considered feasible, whereas a rate <33.3% would be considered feasible and worthy of further study for efficacy. Discontinuation rates at 2 yrs will be estimated by Kaplan Meier with 95% confidence bands. The total sample size is 120 pts, providing 92% power to reject the null hypothesis using a one-sided alpha = 0.025, and accounting for a censoring rate of up to 20% over the 2 yrs. Secondary endpoints include AE graded by CTCAE 4.0 and adherence to oral therapy. Two interim analyses for futility are planned when 66% and 100% of pts have received 6 mos of therapy. Clinical trial information: NCT02040857.
Clonal Evolution Predicts Poor Prognosis in Chronic Lymphocytic Leukaemia and Is Possibly a Worse Prognostic Factor Than 17p Deletion: A Population Based Cohort study of FISH Testing in British Columbia, Canada
Authors: Krystal Bergin, Alina S. Gerrie, Steven J.T. Huang, Khaled M Ramadan, Aly Karsan, Monica Anne Hrynchak, Chinmay B. Dalal, Helene Bruyere, Adam C. Smith, Cynthia L. Toze, Tanya L. Gillan
Journal: Blood (2012)
NIMG-27. LANGUAGE LATERALIZATION ASSESSED BY MAGNETOENCEPHALOGRAPHY IMAGING USING THREE DIFFERENT LANGUAGE TASKS
Authors: Elke De Witte, Leighton Hinkley, Danielle Mizuiri, Coleman Garrett, Susanne Honma, Heidi Kirsch, John Houde, Mitchel S. Berger, Sri Nagarajan
Journal: Neuro-Oncology (2016)

Magnetoencephalography (MEG) is a valuable alternative to the Wada test for defining preoperative language lateralization in neurosurgical candidates. Laterality indexes (LI) measured by MEG have shown high concordance with Wada data. Verb generation is typically used during preoperative mapping, but other language tasks such as repetition and picture naming have been administered. A preoperative MEG paradigm has been developed to determine language lateralization with excellent predictive value using verb generation (Findlay et al., 2012). However, this paradigm has not yet been tested nor adapted for other language tasks. In this study, 7 glioma patients underwent both the Wada test and MEG in the preoperative phase. MEG was recorded using a 275-channel whole head biomagnetometer during three different language tasks: verb generation, picture naming and non-word repetition. MEG data was reconstructed in source space using an adaptive spatial filtering technique in Nutmeg. Optimized time windows and regions of interest (ROIs) for each task were determined by examining oscillations in the beta band (12-30Hz), which were concordant with Wada. LI was estimated by comparing changes in beta power across frontal and temporal ROIs for both stimulus and response locked analyses. As has been previously reported, increased beta suppression was observed across the frontal and temporal lobes for verb generation representative of language dominance. Using identical time windows and ROIs in the picture naming and non-word tasks, we identified concordance with Wada test in respectively 5/6 subjects and 6/7 subjects. Based on the differences found in reaction times and cortical activation comparing the three tasks, time windows and ROIs were adjusted to ensure full concordance. This pilot study allows us to define the optimal parameters for MEG laterality calculations in language tasks outside of verb generation. In addition, new insights into the spatiotemporal dynamics of language lateralization are provided.
TROPICS 2: A Phase III, Open-Label, Single-Arm Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters.
Authors: Cameron Tebbi, John Costanzi, Robert J Shulman, Luke Dreisbach, Brian R Jacobs, Martha Blaney, Mark Ashby, Barbara S Gillespie, Susan M Begelman
Journal: Blood (2009)
273P Cisplatin in combination with pemetrexed in the treatment of patients for advanced malignant peritoneal mesothelioma: Retrospective study of 21 cases
Authors: K. Shingo, K. Kuribayashi, E. Fujimoto, Y. Koda, Y. Negi, E. Shibata, T. Otsuki, K. Mikami, T. Nakano
Journal: Annals of Oncology (2016)
Effect of Iron Intake on Control of Body Iron in Patients with Thalassemia Major Treated with Deferasirox (Exjade®, ICL670).
Authors: A. Cohen, G. Masera, N. Zoumbos, Z. Uysal, D. Boulet, N. Watman, S. Loggetto, H. Opitz, I. Gathmann, D. Alberti
Journal: Blood (2005)
Abstract 1751: Coronary Plaque Characteristics on Multi-Slice Computed Tomography in Stable Versus Unstable Angina Pectoris
Authors: Gabija Pundziute, Joanne D Schuijf, Wouter J Jukema, Eric Boersma, Albert de Roos, Ernst E van der Wall, Jeroen J Bax
Journal: Circulation (2006)
MicroRNA-155 promotes G-CSF-induced mobilization of murine hematopoietic stem and progenitor cells via propagation of CXCL12 signaling
Authors: T Itkin, A Kumari, E Schneider, S Gur-Cohen, C Ludwig, R Brooks, O Kollet, K Golan, E Khatib-Massalha, C M Russo, J D Chisholm, A Rouhi, H Geiger, E Hornstein, W G Kerr, F Kuchenbauer, T Lapidot
Journal: Leukemia (2017)
Effect of non-attenders on the potential of a primary care programme to reduce cardiovascular risk in the population
Authors: G. Davies, S. Pyke, A.-L. Kinmonth
Journal: BMJ (1994)

<h3>Abstract</h3> <b>Objectives</b>: To determine the feasibility of enrolling non-attenders of a population based cardiovascular risk reduction programme (the British family heart study) into a further, similar programme and to assess the effect of non-attendance on the effectiveness of the programme. <b>Design</b>: Follow up of non-attenders by practice nurses, including home visits if necessary, to administer questionnaires and obtain physiological measurements. <b>Setting</b>: Eight general practices across England, Scotland, and Wales. Subjects—Non-attenders in a cardiovascular risk factor screening and intervention programme compared with attenders. <b>Main outcome measures</b>: Number of nonattenders enrolled; sociodemographic characteristics; personal and family history of coronary heart disease; cardiovascular risk factors; and total coronary risk score. <b>Results</b>: Data were collected from 106 (17%) of the 608 non-attending families (99 men and 42 women). Of the 543 non-attending families from five practices that attempted complete follow up, 256 had moved away or died. Only 76 were eventually enrolled into the study. The prevalence of coronary heart disease and a family history of coronary heart disease were similar among non-attenders and attenders as were the individual coronary risk factors studied except smoking. Women non-attenders were more likely to be current cigarette smokers than attenders (15/42 (upsilon) 202/948, P = 0.02). <b>Conclusions</b>: The intensive follow up of nonattenders resulted in real intervention opportunities in only a small number. Since the effect of any intervention in a population is reduced by nonattendance audit of preventive medical programmes aimed at the population should allow for the effect of non-attenders on the overall results.
Improving detection of Lynch syndrome using a reflex immunohistochemistry algorithm for all patients with newly diagnosed colorectal cancer.
Authors: Minggui Pan, Elizabeth Hoodfar, JoAnn Bergoffen, Regan Fulton, Laura Hofmeister, Annette Chavez, Dan Li
Journal: Journal of Clinical Oncology (2012)

98 Background: Identifying patients with Lynch syndrome has profound impact on the clinical care of patients and their families. Previous guidelines based on family history alone have shown low sensitivity. In our medical center, the detection rate of Lynch syndrome was &lt;1% among colorectal cancer cases. Methods: We have developed a system-based algorithm using centralized testing by immunohistochemistry (IHC) for four mismatched repair (MMR) proteins (MLH1, MSH2, MSH6, and PMS2) as a screening method for all newly diagnosed colorectal cancer patients, followed by step wise testing of BRAF mutation, MLH1 promoter hypermethylation, +/- microsatellite instability, and germline mutation. Results: From April 1, 2011, to July 11, 2012, we have screened 116 patients. IHC detected absent expression of at least one of the MMR proteins in 18 cases. Three cases showed missing expression of MSH2/MSH6 and the presence of a germline mutation in MSH6 was confirmed in two cases. The newest case is still being investigated for germline mutation. Of the remaining 15 cases, 10 showed the presence of BRAF V600E mutation, two showed hypermethylation of the MLH1 promoter, and one showed germline MLH1 mutation. Two cases showed no BRAF V600E mutation, no MLH1 promoter hypermethylation or germline gene mutation. Overall, of 116 cases, three cases have confirmed Lynch syndrome with the detection of a germline mutation, two cases most likely have Lynch syndrome but without any detectable germline mutation of MLH1 or PMS2 using the current detecting methods. Conclusions: Our system-based screening algorithm using reflex immunohistochemistry of four MMR proteins has resulted in excellent detection rate of approximately 4% to 5% (5 out of 116 cases), consistent with the expected Lynch syndrome prevalence rate in the population. This represents a marked improvement over our previous family history-based approach in Lynch syndrome screening.
Incidence of germline BRCA mutation in patients with ER-low positive/PR negative/HER-2 neu negative tumors.
Authors: Rachel Ann Sanford, Juhee Song, Angelica M. Gutierrez-Barrera, Jennifer Keating Litton, Isabelle Bedrosian, Constance T. Albarracin, Vicente Valero, Banu Arun
Journal: Journal of Clinical Oncology (2014)

2 Background: The 2011 ASCO/CAP guidelines recommend that breast cancers with estrogen receptor (ER) staining as low as 1% on immunohistochemistry be considered ER-positive. In practice, there remains significant variability in what clinicians consider ER-positive versus ER-negative. Current NCCN guidelines recommend that patients under age 60 with triple-negative breast cancer (TNBC) be referred for genetic counseling and consideration of germline BRCA mutation testing. With the 2011 ASCO/CAP guidelines, the definition of TNBC has changed to exclude patients with ER low-positive (1-9%) tumors; hence patients with ER-low positive tumors (formerly considered ER negative) may not be referred for genetic counseling and BRCA testing. This may lead to “undertesting” of appropriate patients. The incidence of BRCA germline mutations in patients with ER-low positive versus ER-negative (0%) tumors is unknown. We sought to identify whether the incidence of BRCA mutation differed between patients with ER-negative/PR-negative/HER-2 neu negative tumors and patients with ER-low positive/PR-negative/HER-2 neu negative tumors. Methods: We performed a review of a prospectively maintained research database of all patients with ER &lt; 10%, PR 0% and HER-2 neu–negative breast cancers who were referred for genetic risk assessment and testing for BRCA mutation at UT MD Anderson Cancer Center. Results: Of 144 patients who underwent BRCA mutation testing, 22 (15%) had ER-low positive tumors while 122 (85%) had ER-negative tumors. Among patients with ER-low positive tumors, 7 of 22 (31.8%) were found to have a deleterious BRCA 1/2 mutation, while 33 of 122 (27%) with ER-negative tumors were found to have a deleterious BRCA 1/2 mutation. The incidence of deleterious BRCA 1/2 mutation in patients with ER-low positive tumors versus those with ER-negative tumors was not statistically significantly different (p = 0.6457). Conclusions: The rate of deleterious BRCA 1/2 germline mutations in ER-negative versus ER-low positive (1-9%) breast cancer is similar. Therefore, we strongly recommend that BRCA testing continue to be offered to women under age 60 with tumors that are ER-low positive/PR-negative/HER-2 neu negative.
Tiotropium Respimat® 2.5 μg Add-on to ICS or ICS+controller medications Improves Lung Function in Adults and Adolescents With Mild, Moderate, or Severe Symptomatic Asthma
Authors: William E. Berger, Eli O. Meltzer, Anna Unseld, Asif Shaikh, Michael Engel
Journal: Journal of Allergy and Clinical Immunology (2017)
Presence of Cytomegalovirus DNA in the Whole Blood Is Associated with the Risk of Bronchial Asthma
Authors: Marek L. Kowalski, Aleksandra Wardzynska, Miroslawa Studzinska, Malgorzata Pawelczyk, Zbigniew Jan Lesnikowski, Edyta Paradowska
Journal: Journal of Allergy and Clinical Immunology (2017)
A Case of Histoplasmosis and Renal Extranodal Marginal Zone Lymphoma in a Patient with Common Variable Immunodeficiency (CVID) and Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD)
Authors: Andrew T. Dang, Gene Schwartz, LaQuita Jones, Michael J. Absalon, Richard L. McMasters, Amal H. Assa'ad
Journal: Journal of Allergy and Clinical Immunology (2017)
P04.04 Ex vivo expansion of human glioma-infiltrating lymphocytes alters the exhaustion phenotype of T cells
Authors: K. L. Deumelandt, T. Bunse, L. Bunse, J. K. Sonner, C. Thomé, M. Nadji-Ohl, W. Wick, M. Platten
Journal: Neuro-Oncology (2016)

INTRODUCTION:The treatment of glioblastoma multiforme (GBM) is a major challenge of neuro-oncology.Despite aggressive therapeutic strategies including surgery and radio-chemotherapy, median survival remains extremely low.This points to the urgent need for alternative treatment strategies such as immunotherapy.Immunological escape mechanisms, involving the Natural Killer Group 2, member D (NKG2D) receptor-ligand system, play a major role in tumor progression.Cell-bound NKG2D-ligands such as MHC class I related molecule A and B (MICA and MICB), and the UL-16 binding protein family (ULBP1-6) are recognized by the NKG2D-receptor (NKG2Dr) and trigger cytotoxic effector functions in NK-cells and T-cell subsets.By releasing soluble NKG2DL (sNKG2DL), which then bind to NKG2Dr, tumor cells inhibit the killing potential of the effector cells.Numerous studies documented the importance of NKG2D-system in vitro GBM-model systems.Here, we aimed to analyze NKG2D-system in GBM-patients ex vivo.MATERIALS AND METHODS: Until now, 37 GBM patients and 19 healthy controls (HCs) have been included in the study.A total of 24 GBM patients were on medication with dexamethasone prior to surgery.We analyzed serum levels of sNKG2DLs in HCs and GBM patients before and 3 months after surgery and radio-chemotherapy via Luminex-based multiplex assay.Absolute cell numbers of distinct immune cell subsets and the expression of NKG2Dr were analyzed by flow cytometry.NKG2DLexpression on GBM primary cell cultures was studied via flow cytometry and western-blotting.RESULTS: Our data show that in comparison to healthy controls GBM patients show reduced numbers of leukocytes and cytotoxic effector cells in peripheral blood, but elevated numbers of immunosuppressive cell subsets.Whereas NKG2Dr is not detectable in primary cell cultures, the tumor cells moderately express NKG2DL and release sNKG2DL into the culture medium.Serum levels of sNKG2DL are differentially modulated in GBM patients when comparing pre-to 3 months postop.This effect is independent of medication with dexamethasone.CONCLUSION: GBM patients seem to have impaired cytotoxic immune response compared to HCs.As NKG2DL are released by the tumor cells, this effect might also be generated via sNKG2DL.Nevertheless, serum levels of NKG2DL do not decline after treatment in most patients.A better understanding of the mechanisms regulating the NKG2D-system in GBM patients will be crucial for the development of new therapeutic strategies targeting the NKG2D system.
516P Utility of colonoscopy in diagnosing familial adenomatous polyposis (FAP) among patients (pts) with desmoid tumors (DT)
Authors: Z. Zhang, M. Teo, K.C. Soo, M.H. Tan, A.Y.-F. Chung, W.L. Goh, S. Sathiyamoorthy, K. Sittampalam, J. Teh, F. Chin, S.-T. Li, J. Ngeow, M. Farid, R. Quek
Journal: Annals of Oncology (2016)
Novel Mechanistic Insight Into Mobilization of Hematopoietic Stem/Progenitor Cells (HSPCs): Complement Cascade and Membrane Attack Complex Activated in Bone Marrow Sinusoids During Mobilization Release From Erythrocytes Sphingosine-1 Phosphate – An Underappreciated Chemoattractant Executing Egress of HSPCs.
Authors: HakMo Lee, Marcin Wysoczynski, Wan Wu, Rui Liu, Magdalena Kucia, Anna Janowska-Wieczorek, Janina Ratajczak, Mariusz Z Ratajczak
Journal: Blood (2009)
Effect of Age and Previous Autologous Transplant on Treatment-Related Mortality and GVHD in 140 Patients Treated with Reduce-Intensity Conditioning and Allograft for Advanced Hematological Malignancies.
Authors: Paolo Corradini, Francesco Zallio, Jacopo Mariotti, Pinuccia Valagussa, Anna Dodero, Marco Bregni, Fabio Ciceri, Andrea Bacigalupo, Moira Lucesole, Francesca Patriarca, Andrea Rambaldi, Rosanna Scimè, Giuseppe Bandini, Alessandro M. Gianni, Corrado Tarella, Attilio Olivieri
Journal: Blood (2004)
A phase 1 study of single agent veliparib in Japanese subjects with advanced solid tumors
Authors: K. Matsumoto, K. Tamura, H. Yoshida, T. Nishikawa, Y. Imai, A.M. Miyasaka, T. Onoe, S. Yamaguchi, C. Shimizu, K. Yonemori, T. Shimoi, M. Yunokawa, H. Xiong, H. Hashiba, T. Kiriyama, T. Leahy, S. Shepherd, K. Fujiwara
Journal: Annals of Oncology (2016)
TBI and Allogeneic BMT Do Not Appear To Hinder Growth in Pediatirc Patients with AML Treated on POG 9421 (Now Children’s Oncology Group).
Authors: Kimo Stine, David Becton, Gary Van Houten Dahl, Yaddanapudi Ravindranath, Susana C. Raimondi, Fred Behm, Myron Chang, Robert Arceci
Journal: Blood (2006)
Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure
Authors: Alberto Aimo, Giuseppe Vergaro, Andrea Ripoli, Antoni Bayes-Genis, Domingo A. Pascual Figal, Rudolf A. de Boer, Johan Lassus, Alexandre Mebazaa, Etienne Gayat, Tobias Breidthardt, Zaid Sabti, Christian Mueller, Hans-Peter Brunner-La Rocca, W.H. Wilson Tang, Justin L. Grodin, Yuhui Zhang, Paulo Bettencourt, Alan S. Maisel, Claudio Passino, James L. Januzzi, Michele Emdin
Journal: JACC Heart Failure (2017)
Zika Virus Pathogenesis and Tissue Tropism
Authors: Jonathan J. Miner, Michael S. Diamond
Journal: Cell Host & Microbe (2017)

Although Zika virus (ZIKV) was isolated approximately 70 years ago, few experimental studies had been published prior to 2016. The recent spread of ZIKV to countries in the Western Hemisphere is associated with reports of microcephaly, congenital malformations, and Guillain-Barré syndrome. This has resulted in ZIKV being declared a public health emergency and has greatly accelerated the pace of ZIKV research and discovery. Within a short time period, useful mouse and non-human primate disease models have been established, and pre-clinical evaluation of therapeutics and vaccines has begun. Unexpectedly, ZIKV exhibits a broad tropism and persistence in body tissues and fluids, which contributes to the clinical manifestations and epidemiology that have been observed during the current epidemic. In this Review, we highlight recent advances in our understanding of ZIKV pathogenesis, tissue tropism, and the resulting pathology and discuss areas for future investigation.
21P Identification of the novel molecules mediating gastric cancer invasion based on genomic analysis of cancer-associated fibroblasts
Authors: T. Ishimoto, K. Miyake, T. Nandi, M. Yashiro, K.K. Huang, K. Arima, D. Izumi, Y. Baba, H. Baba, P. Tan
Journal: Annals of Oncology (2016)
Validation of a Predictive Formula for Collection of Hematopoietic Progenitor Cells (HPC) By Leukapheresis at 2 Institutions Using 4 Different Machine Protocols
Authors: Eric R Rosenbaum, Patrick Wuchter, Michael Hundemer, Petra Pavel, Mathias Witzens-Harig, Hartmut Goldschmidt, Bart Barlogie, Anthony Ho, Michele H. Cottler-Fox
Journal: Blood (2014)
Interim safety results of eribulin (E) combined with ramucirumab (RAM) in patients (pts) with advanced metastatic breast cancer (MBC).
Authors: Denise Aysel Yardley, Cynthia R. C. Osborne, Paul D. Richards, Brooke R. Daniel, Michael A. Danso, Anne Favret, Jane Bromund, Yanzhi Hsu, Ayman B. Ibrahim
Journal: Journal of Clinical Oncology (2012)

110 Background: VEGF-mediated angiogenesis contributes to breast cancer (BC) pathogenesis. RAM (IMC-1121B), a fully human IgG1 monoclonal antibody (MAb), targets VEGFR-2, blocking the interaction of VEGF ligands and VEGFR‑2. DC101 (murine anti-VEGFR-2 MAb) impairs vascular function and increases tumor hypoxia in xenograft BC models and inhibits tumor growth in cytotoxic-resistant models. E is a novel non-taxane microtubule inhibitor indicated in MBC pts who have received ≥2 prior chemotherapy regimens, including an anthracycline and a taxane. It is hypothesized that addition of RAM to E as 3rd-5th line therapy in MBC will result in an improvement of median PFS in this ongoing, multicenter, US study. A planned safety analysis of an initial cohort is reported. Methods: Pts with locally recurrent or MBC (HER2+ or HER2-) and 2-4 prior chemotherapy regimens are randomized 1:1 to receive RAM+E or E (E 1.4 mg/m 2 Days 1, 8; RAM 10 mg/kg Day 1; q21 days). Pts are stratified by TNBC and prior antiangiogenic therapy status and must have ECOG PS 0-1 and normal LVEF. Planned accrual: 134 pts. Results: Evaluable pts (n=13, 8 RAM+E) received ≥1 dose of RAM+E or E and completed 2 cycles of therapy (or discontinued prior to completing the initial 2 cycles). Median age is 55 yrs. Assessment of adverse events (all cause) revealed nausea, fatigue, headache, and neutropenia were more frequent for RAM+E; anemia was more frequent for E. G1 sensory neuropathy was reported for 1 pt in each arm. One RAM+E pt experienced G3 febrile neutropenia and odynophagia, recovered within a week, and subsequently received reduced dosage (E = 1.1 mg/m 2 ; RAM = 8 mg/kg). No deaths are reported. The safety assessment committee recommended to continue the trial unmodified. Conclusions: Based on preliminary data, the combination of RAM+E demonstrates an acceptable toxicity profile. Accrual continues, with planned updated safety and dose intensity data to be presented at the meeting. [Table: see text]
Safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving breast cancer resistant protein (BCRP) substrate chemotherapy agents
Authors: L. Schwartzberg, K. Jordan, B.L. Rapoport, I. Schnadig, M. Chasen, S. Arora, S. Barbour, D. Powers, R. Navari
Journal: Annals of Oncology (2016)